LeonaBio (LONA) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
18 Mar, 2026Opening remarks and agenda
Meeting called to order by the Chairperson, with board members, senior management, legal counsel, and Inspector of Election present.
Procedures for orderly conduct and voting outlined at the start.
Specific resolutions to be voted on
Approval of issuance of 5,502,402 shares of common stock via Surmodics pre-funded warrant exercise under Nasdaq Rule 5635(a)(2).
Approval of issuance of shares to Surmodics if beneficial ownership exceeds 19.99% post-exercise, per Nasdaq Rule 5635(b).
Approval of issuance of shares to Perceptive Advisors if beneficial ownership exceeds 19.99% post-exercise, per Nasdaq Rule 5635(b).
Approval of the 2026 Equity Incentive Plan.
Amendment to increase authorized shares of common stock.
Authorization to adjourn the meeting if necessary to solicit additional proxies.
Corporate governance
Only stockholders of record as of January 27, 2026, were eligible to vote.
Quorum confirmed with majority of shares present or represented by proxy.
Inspector of Election appointed and oath filed with meeting minutes.
Latest events from LeonaBio
- Secured lasofoxifene license, raised $90M, and advanced clinical pipeline amid higher R&D spend.LONA
Q4 202526 Mar 2026 - Proposal 6 is now routine, enabling discretionary broker voting at the March 2026 meeting.LONA
Proxy Filing10 Mar 2026 - Shareholders to vote on major share issuances, new equity plan, and increased authorized stock.LONA
Proxy Filing23 Feb 2026 - Shareholders to vote on key share issuances, new equity plan, and major charter amendment.LONA
Proxy Filing4 Feb 2026 - Exclusive lasofoxifene license and $236M financing drive late-stage cancer and ALS programs.LONA
Status Update3 Feb 2026 - Fosgonimeton is tested in a pivotal Alzheimer's trial using GST, with results due in 2H24.LONA
Status Update3 Feb 2026 - Pivotal Alzheimer's trial readout expected in fall, with strong cash position and ALS expansion planned.LONA
Goldman Sachs 45th Annual Global Healthcare Conference3 Feb 2026 - LIFT Alzheimer's trial nears data, with strong interim results and ALS program advancing.LONA
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Registering 5.5M shares for resale, proceeds to fund cancer and ALS drug development.LONA
Registration Filing20 Jan 2026